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Abstract 
 
Different neurophysiological methods such as evoked potentials (EP), testing of the 
autonomic nervous system (ANS) or polysomnography have the potential to detect clinically 
silent lesions or to confirm the existence of an association between a clinical symptom and 
multiple sclerosis (MS); previously undetected by MRI. Therefore, in the most recent MRI 
criteria for the diagnosis of MS (MAGNIMS consensus guidelines), neurophysiological 
confirmation of optic nerve dysfunction (slowed conduction on visual EP), support 
dissemination in space and, in patients without concurrent visual symptoms, dissemination in 
time. In this chapter we will review the existing evidence regarding the role of different 
neurophysiological tests (specifically the role of EPs, autonomic nervous system testing and 
sleep testing in MS) in the diagnosis and management of MS. 
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Introduction 
 
Multiple sclerosis (MS) is a chronic idiopathic demyelinating illness of the central nervous 
system and it is the leading cause of disability in young adults. In the diagnosis of MS, three 
main principles are applied: demonstration of dissemination in space (DIS), demonstration of 
dissemination in time (DIT), and reasonable exclusion of alternative explanations for the 
clinical presentation. The demonstration of DIS and DIT is heavily influenced with MRI, and 
since its introduction, this method has become the cornerstone in the diagnosis of MS with 
various MRI criteria applied over time (1,2). The last version of the McDonald criteria allows 
to make a diagnosis of MS in patients with typical clinically isolated syndrome (CIS). 
Despite these advancements, there is still a poor correlation between clinical symptoms and 
MRI findings in a substantial proportion of MS patients (3). Different neurophysiological 
methods such as evoked potentials (EP), testing of the autonomic nervous system (ANS) or 
polysomnography have the potential to detect clinically silent lesions or to confirm the 
existence of an association between a clinical symptom and MS; previously undetected by 
MRI. A nice example of the latter are EP, which have been widely used in MS, although their 
clinical use has been reduced after the introduction of MRI. This is not always justifiable 
since the information provided by evoked potentials is more related to function, unlike the 
information provided by MRI which is more related to anatomy. (4) Therefore in the most 
recent MRI criteria for the diagnosis of MS (MAGNIMS consensus guidelines), 
neurophysiological confirmation of optic nerve dysfunction (slowed conduction on visual 
EP), support dissemination in space and, in patients without concurrent visual symptoms, 
dissemination in time. (5) 
In this chapter we will review the existing evidence regarding the role of different 
neurophysiological tests (specifically the role of EPs, autonomic nervous system testing and 
sleep testing in MS) in the diagnosis and management of MS. 
 
 
Evoked potentials in multiple sclerosis  
 
The role of EPs in the evaluation of MS has changed over time primarily due to advances in 
neuroimaging technology, dominantly the MRI. In contrast with MRI, EPs provide 
information about functionality and pathophysiological involvement of a certain 
neuroanatomic pathway (6) and their clinical utility is based on their ability to reveal 
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subclinical involvement of a sensory system in the presence of signs/symptoms suggestive for 
demyelinating disease (7).  
In routine clinical practice, most frequently used EPs are: pattern reversal visual EPs (VEPs), 
brainstem auditory EP (BAEP), short latency somatosensory EP (SSEP), and motor evoked 
potentials (MEPs) (6).  
VEPs are widely used in assessment of patients with clinical signs of optic neuritis (ON) as 
well as in evaluation of asymptomatic involvement of visual pathways in patients with MS. 
The most common finding in acute ON is delayed latency of wave P100 together with 
amplitude reduction (8). With recovery from ON, the amplitude improves but latency usually 
persistently increases.  The sensitivity of VEPs in patients with MS and a history of optic 
neuritis is about 77% to 100% while the frequency of abnormal VEPs in overall patients with 
MS varies between studies; from 42% - 100% (9,10).  According to new MAGNIMS criteria, 
VEP is reintroduced as part of diagnostic MS criteria (5).  
BAEPs are used to detect and approximately localize symptomatic, as well as asymptomatic, 
dysfunctions of the auditory pathways within the auditory nerve and brainstem. The most 
common BAEP pathological findings in patients with MS reflect dysfunction of the upper or 
lower brainstem, including increased wave I-III (lower brainstem) or III-V (upper brainstem) 
interlatencies (11). According to published literature, overall sensitivity in evaluation of 
brainstem involvement is low (7,12,13) and it is inferior to MRI and vestibular evoked 
myogenic potentials (VEMP) (12).  
SSEP, elicited from the upper and lower limbs, evaluate dorsal columns and the thalamo-
cortical sensory system. The diagnostic value of SSEP is most pronounced in diagnostic 
evaluation of patients with no evidence of demyelinating lesions on the spinal MRI. Tibial 
SSEP is considered to be among the most valuable EPs (14), giving pathological findings in 
up to 80% of patients with MS who do not have sensory symptoms and signs (15). 
Pathological findings commonly found in tibial SSEP are increased latencies of upper 
thoracic and cortical response. SSEPs of the median nerve add additional value because 
through the P14 wave they provide information about the degree to which the lower brainstem 
is affected. Abnormalities of P14 were found to be a significant contributor to the functional 
brainstem assessment battery.  
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MEPs are evaluating the corticospinal tract and together with SSEPs represent a valuable 
neurophysiological method for evaluation of the spinal cord. Beside its diagnostic value, MEP 
studies in MS serve as an indication of corticospinal pathway dysfunction (16). The 
pathological finding in MS is an increased central motor conduction time (CMCT), which is 
found to be related with EDSS values (17) and can predict long term disability (18).  
Vestibular evoked myogenic potentials (VEMPs) have been proven to be useful in the 
assessment of brainstem involvement in MS (3). VEMP presents a myogenic response to a 
loud acoustic stimulus and is divided into two parts, depending where the myogenic response 
is measured: cervical VEMP (ipsilateral sternocleidomastoid muscle, waves P13 and N23), 
which provides information about vestibulospinal pathways; and ocular VEMP (contralateral 
ocular muscle, waves N10 and P13), which provides information about the functionality of 
vestibuloocular reflex. The sensitivity for MS patients varies from 30% to 100% and results 
are characterized with an absent response, prolonged latencies and reduced amplitudes of 
major waves (19, 20). According to some studies, VEMP is superior to clinical examination, 
MRI and BAEP in detection of brainstem lesions (21). 
 
 
The EP score 
 
Different modalities of evoked potentials show correlation with disability and disease 
progression in MS patients, so it could be assumed that a combination of different evoked 
potential could provide even more useful information. VEP, BAEP, SSEP and MEP could be 
combined into a multimodal EP score, a specific scale calculated according to normative 
values for each of the EPs.  A different degree of the significance is assigned to each of the 
types of abnormalities (prolonged latencies, reduced amplitude, absent response), and the 
level of significance is specific for every study. If the EP score consists of VEP, SSEP of 
upper and lower extremities where a normal response is scored with 0, prolonged latency with 
1, reduced amplitude with 2 and an absent response with 3; then a patient with prolonged 
VEP latencies on the left side, a reduced amplitude of P40-N50 complex on the left side for 
tibial nerve SSEP and an absent response on the right side for the medial nerve SSEP has an 
EP score of 6 (1+2+3), as presented on Figure 1. The EP score could be defined with ordinal 
values calculated according to normative values or with different transformations of raw EP 
data (z transformation). 
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Multimodal evoked potentials (mEPs measure and moderately predict clinically relevant 
disease activity in patients with early relapsing remitting MS (22). The mEPS at baseline has 
shown correlation with EDSS after 24 months and changes in mEPS correlated with changes 
in EDSS, where patients with EDSS progression showed stronger mEPD deterioration than 
clinically stable patients (22). A combination of VEP, BAEP, SSEP and MEP results gathered 
in an EP score has demonstrated a significant correlation between the EP score and EDSS 
score at the time of neurophysiological study and at 1, 3 and 5 years of follow-up, particularly 
for MEP and SEP; thus, giving rise to the evidence that EPs, particularly MEP and SEP, have 
significant value in predicting neurological disability (23). Patients with an EP score at a 
baseline higher than the median value had an 72.5% increased risk of disability progression at 
follow-up; meanwhile, patients with a lower EP score had a risk of only 36.3% (24), 
suggesting a predictive role of the multimodal EP score. This was confirmed by the fact that 
patients with worsening at follow-up had a significantly worse global EP score at baseline in 
comparison with patients without worsening (24).   
Different EPs (VEP, BAEP, SSEP and MEP) associated with the EP score have shown 
moderate and useful correlation with clinical status in patients with primary progressive MS – 
PPMS (25). The numerical score based on VEP, SSEP and MEP results correlates well with 
disability in PPMS and allows some prediction of the disease course over three years (26).  
Combination of VEP, BAEP and SSEP could be used as an outcome variable for determining 
the efficiency of a particular treatment (27). Treatment effects did not show any significance 
for EDSS, but there was improvement in EP score (mainly because of the significant decrease 
in VEP score) between different treatment groups (27).  
Finally, brainstem involvement in MS patients is very important in the prediction of disease 
progression. In an EP score that includes BAEP (24), it has not been shown to have any 
statistically significant correlation between BAEP and EDSS, neither on baseline or follow-up 
suggesting that BAEP is insufficient in the neurophysiological evaluation of the brainstem in 
MS and it is necessary to include another measure of brainstem dysfunction.  
It is known that VEMP is superior to BAEP in detection of brainstem involvement and 
because of that, the VEMP score was designed. The VEMP score presents interpretation of 
VEMP results quantified according to cut-off values (0 = normal response, 1 = prolonged 
latency, 2 = reduced amplitude, 3 = absent response) calculated separately for every recording 
position and combined in a unique score, with a minimal value of 0 and maximal of 12.  The 
VEMP score is higher for MS patients with clinical signs of brainstem involvement, correlates 
with EDSS and disease duration and, according to multiple regression analyses, the VEMP 
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score is a statistically significant predictor for EDSS (28). These results indicate that the 
VEMP score is sensitive to brainstem involvement and it could replace BAEP in the EP score 
and improve its sensitivity to brainstem involvement.  
 
Autonomic dysfunction in multiple sclerosis 
 
The importance of the autonomic nervous system (ANS) is well appreciated, as it is 
paramount for regulating function of each and every organ in the body. However, our capacity 
to test its activity somewhat lags behind its significance. The reason is that the ANS is 
unavailable for direct assessment. As we are unable to test it directly, we must rely on testing 
its reflexes. This kind of testing is mainly related to cardiovascular and sudomotor autonomic 
reflexes. The cardiovascular autonomic system is tested by the following methods: blood 
pressure and heart rate response to Valsalva maneuver, heart rate variability during deep 
breathing and blood pressure and heart rate changes during tilt table testing (29). Sudomotor 
function is most precisely assessed by the Quantitative Sudomotor Axon Reflex testing (30). 
Combining all of these tests we can quantify the severity of ANS dysfunction using the 
Composite Autonomic Scoring Scale and render the impairment more precisely using the 
adrenergic, cardiovagal and sudomotor indexes (31). Another method of ANS assessment, 
nowadays gaining popularity, is the analysis of heart rate variability (HRV). In this method 
differences in sympathetic and parasympathetic effects on cardiac activity, reflected in the 
variability of beat-to-beat R-R intervals on ECG, are exploited to estimate the level of activity 
of each ANS branch (32). 
Cardiovascular ANS dysfunction is commonly present in multiple sclerosis (MS) (33). 
Furthermore, it is recognized in the early stages of the disease as the clinically isolated 
syndrome (34). Altogether, it affects up to two thirds of patients during the course of the 
disease (35). It is mainly caused by demyelinating lesions located in the periventricular region 
of the fourth ventricle that affect the autonomic nuclei, as well as due to the descending and 
ascending autonomic pathways in the medulla also being affected (36,37). Half of MS 
patients experience orthostatic intolerance with presenting symptoms that can be insidious 
and nonspecific such as dizziness, lightheadedness and general malaise (38). The failure of 
blood pressure to remain stable in an upright position in MS patients is due to impaired 
sympathetic vasocostrictory reflex that is responsible for maintaining adequate blood pressure 
during postural change (39). This, in turn, results in orthostatic hypotension (OH), a 
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significant and sustained decrease of blood pressure upon standing (40) (Figure 2). The 
symptoms are caused by cerebral hypoperfusion and are typically induced by standing and 
quickly resolve when lying flat. If the fall of blood pressure is sufficiently pronounced it can 
lead to falls and even loss of consciousness with the hazard of traumatic injuries. Patients with 
OH are commonly fatigued and, using the HRV analysis, it has been found that reduced 
sympathetic activity during standing correlates with the Modified Fatigue Impact Scale in MS 
patients (41). Another variety of orthostatic intolerance is the postural orthostatic tachycardia 
syndrome (PoTS). It is characterized by sustained heart rate increase on orthostatic challenge 
without concomitant OH (40). PoTS is recognized to be present in MS more frequently than 
in healthy controls and its presence is explained by demyelinating brainstem and hemispheral 
lesions disrupting the physiological heart rate variability modulation (42,43). Although the 
true significance of PoTS in MS is not completely elucidated, it is known that PoTS patients 
have a restricted ability to exercise and an increased sensation of fatigue, which may 
aggravate preexisting symptoms in MS. Another factor adding to the problem of fatigue in 
MS is reduced vagal activity that is seen to occur at a younger age in MS (44).  
MS patients can also present with more severe cardiovascular symptoms, which can actually 
be secondary to disease activity. Acute central nervous system lesions, including 
demyelinating lesions, can induce an increased release of catecholamines causing necrotic 
changes in cardiac myocytes and disrupt the endocardial conduction system leading to 
arrhythmias such as sinus bradycardia or paroxysmal atrial fibrillation (45,46,47). There have 
even been reports of cardiogenic shock and pulmonary edema as a presenting symptom of MS 
due to active lesions in the brainstem affecting the solitary tract nucleus (48). Furthermore, 
studies have shown that HRV is reduced in MS patients compared to healthy subjects (49,50) 
and this reduction seems to be related to disease duration (51). This is important since it has 
been found that reduced HRV is associated with an increased risk of cardiac events (52). 
Therefore, the occurrence of cardiac symptoms in an MS patient with no known cardiac 
disease should prompt consideration of MS relapse as a possible etiology. An interesting 
finding is that HRV analysis may also be useful in predicting the known cardiac side effects 
of fingolimod, an immunomodulatory treatment, in an individual MS patient. (53) 
Reduced sweating ability has also been documented in MS patients. Quantitative assessment 
has shown a lower sweating response compared to healthy controls without a disease specific 
pattern (54). The MRI lesion load as well as neurologic disability is associated with 
development of thermoregulatory hypohydrosis. However, sweating impairment can already 
be seen in the early stage of multiple sclerosis, the clinically isolated syndrome (34). These 
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abnormalities of sweating to heat exposure seem to result from the disruption of central 
sudomotor pathways connecting the anterior hypothalamus with the intermediolateral 
columns of the spine (55). It is important to stress that heat intolerance in MS patients can 
lead to pseudorelapses, the so called Uhthoff phenomenon, which underlines the importance 
of adequate thermoregulation in MS. 
Although autonomic dysfunction is usually considered as a consequence of MS activity, the 
interaction is more complex and not completely one-sided. Namely, the ANS participates in 
the regulation of the immunological system via adrenergic and cholinergic receptors on the 
immune cells (56). Its anti-inflammatory effect is mainly based on sympathetic activity that 
inhibits production of Th1-derived proinflammatory cytokines while stimulating production 
of Th2-dervied antiinflammatory cytokines (57). Thus, sympathetic dysfunction, which is 
more pronounced in the relapsing remitting phase, increases inflammation and further 
potentiates MS activity. Therefore, research of ANS dysfunction in MS is not only important 
for the assessment of disease manifestation but also contributes to unfolding the complex 
mechanisms of interaction between MS and the immune system. 
 
 
Sleep disorders in multiple sclerosis 
 
Sleep disorders in multiple sclerosis (MS) are more common than in the general population 
and, depending on the study, they account from 25% to 54% of cases (58). The 
immunological background of disease development in both multiple sclerosis and sleep 
disorders has been proposed as a possible common pathophysiological mechanism and recent 
findings of disrupted melatonin pathways in MS patients suggest a multi-level causative 
mechanism of the development of sleep disorders in MS. Importantly, sleep disorders are 
considered to be one of the crucial etiological factors in development of fatigue, a common 
and debilitating symptom of MS.  More precisely, decreased sleep efficiency detected by 
overnight polysomnography significantly correlated with fatigue and lack of energy in MS 
patients compared to controls (59). Furthermore, a recent study showed that obstructive sleep 
apnea and sleep disturbance in MS patients were significantly associated with multiple-
domain cognitive impairment such as visual memory, verbal memory, executive function, 
attention, processing speed, and working memory (60). However, sleep disorders are 
commonly undiagnosed and untreated in the MS population (61).  
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Although almost all of the major subgroups of sleep disorders such as insomnia, sleep 
disordered breathing, REM sleep behavior disorder, narcolepsy and restless legs syndrome 
have been described in MS patients, a higher prevalence in the MS population than in healthy 
controls was well established for insomnia, obstructive sleep apnea, and restless legs 
syndrome (RLS) (62,63,64).  Insomnia is more frequent in patients with multiple sclerosis 
(40%) than in the general population (10-15%) and it has been proposed that insomnia in MS 
occurs due to a multifactorial etiology associated with MS per se like nocturia, spasticity, pain 
and depression (65). 
Sleep-disordered breathing are disorders characterized by respiratory abnormalities during 
sleep. The most common among them is obstructive sleep apnea (OSA) which is 
characterized by repeated collapse of the upper airway during sleep with consecutive sleep 
fragmentation and intermittent hypoxia resulting in increased daytime sleepiness and higher 
risk for development of atherosclerosis. Multiple sclerosis brainstem lesions could be 
additional risk factors for development of OSA (66).  One study included 62 MS patients and 
32 healthy controls who where evaluated by overnight polisomnography, showed the 
prevalence of obstructive sleep apnea was 58% and 47%, respectively (67).  
A high prevalence of restless leg syndrome (RLS) in MS patients has been confirmed in 
several studies (68,69,70,71) and they have been correlated with disease duration, older age 
and cervical cord lesions.  Distinguishing RLS from other motor and sensory symptoms in 
MS can be difficult. Unlike leg discomfort encountered in RLS which is worse in evening, leg 
spasms, often seen in MS patients, are worse on awakening and can occur at any time of the 
day. 
The prevalence of REM sleep behavior disorder (RBD) in the general population ranges from 
0.38% to 0.5% (72). RBD is a parasomnia characterized by loss of muscle atonia during REM 
sleep and consecutive abnormal motor or verbal behaviors associated with unpleasant dreams 
(73). A study that investigated prevalence of RBD in 135 MS patients and 118 healthy 
individuals using RBD questionnaires found four (2.9%) MS patients and none of the healthy 
controls having RBD (74). There are also case reports of RBD in MS patients which suggest 
that a MS lesion in the proximity of the penduculopontine nucleus causes this disorder of 
REM sleep (75,76).  
In addition to the case series describing narcolepsy features in MS patients (77), a study on 
the secondary causes of narcolepsy has revealed that MS is the fourth most common cause 
after inherited disorders, CNS tumors and brain injury; in this study, 12% of the cases of 
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secondary narcolepsy were due to MS (78).  The fact that both of these diseases are related to 
human leukocyte antigen DQB1*0602 might suggest that similar autoimmune process may be 
important in development of narcolepsy and MS. Finally, hypothalamic MS lesions resulting 
in low CSF hypocretin levels have been described to cause hypersomnia in affected patients 
(79). 
Several humoral immunologic factors, such as IL-1 and TNF alpha, have been implicated in 
development of sleep disorders and sleepiness. Since MS is proven to be characterized by 
immune abnormalities, the notion that MS and sleep disorders share a similar background 
seems plausible. However, sleep disorder should be viewed separately due its differing 
etiopatological grounds. Considering the fact that sleep disorders largely contribute to 
development of fatigue, the most common and debilitating symptom of MS, assessment of 
sleep disorders in multiple sclerosis is important. 
 
 
 
Conclusions 
 
In conclusion, EPs are reliable procedures to predict disability in MS patients. The index of 
global EP alteration (EP score), which combines alterations in VEP, BAEP, motor and 
somatosensory EP, shows significant correlation with the EDSS score at the time of 
neurophysiological study and at 1, 3 and 5 years of follow-up. Furthermore, autonomic 
nervous system dysfunction can lead to an array of clinical symptoms often observed in MS 
patients. There is a connection between dysfunction of autonomic cardiovascular reflexes and 
development of cardiac side effects of several drugs that are used in MS treatment; and 
cardiovascular and thermoregulatory autonomic dysfunctions in MS have considerable 
potential to adversely affect exercise. Finally, sleep disorders largely contribute to fatigue in 
MS, making formal assessment of sleep important.  
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Figures 
 
Figure 1. 
Example of EP score (VEP, SSEP of upper and lower extremities) where normal response is 
scored with 0, prolonged latency with 1, reduced amplitude with 2, and absent response with 
3: presented EP score has value of 6 (1+2+3) 
a) VEP: Prolonged latency of P100 wave = 1;  
b) Tibial nerve SSEP: Reduced amplitude of P40-N50 complex on the left side = 2;  
c) Medial nerve SSEP: Absent response on the right side = 3 
 
 
Figure 2. 
Autonomic nervous system testing in an MS patient showing abnormal blood pressure 
response to Valslava maneuver and significant drop in blood pressure upon tilt-up.  
 
 
